Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the release of five-year follow-up results for the Intismeran vaccine used ...

What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value ...

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

The vaccine maker is expanding beyond its COVID-focused offerings.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...